Mr. Fangzhou Zhang has extensive experience in corporate and mergers & acquisitions, foreign investment, and private equity/venture capital. He specializes in investment, mergers and acquisitions, licensing transactions, and regulatory compliance in the life sciences and healthcare industry. Mr. Zhang has represented numerous domestic and international clients in transaction structuring, legal due diligence, drafting and negotiation of transaction documents, closing matters and post-closing matters. He has experience in sectors including pharmaceuticals (biologics, chemical drugs, and traditional Chinese medicine), medical devices, in vitro diagnostics, healthcare services, wind and photovoltaic power generation, and lithium mining. His past clients include Temasek, PAG, Siemens Healthineers, BD, Roche, Grifols, BioNTech, Gilead, Waters, SQM, Sembcorp Energy, Tencent, Sino Biopharmaceutical, Genor Biopharma, Yangtze River Pharmaceutical, Sinopharm Group, Shanghai Pharmaceuticals, Tasly, BioRay, Innovent Biologics, Zelgen Biopharmaceuticals, Chia Tai Tianqing, and Yiling Pharmaceutical.
Mr. Zhang was recognized as a "Recommended Lawyer" in the field of Life Sciences and Healthcare by The Legal 500 Asia Pacific. The Temasek-led Series C financing of Abogen, in which he participated, was selected as one of China Business Law Journal’s Deals of the Year.
In 2014, Mr. Zhang graduated from the Law School of Wuhan University with a Bachelor of Laws and was named an "Outstanding Graduate." During his studies, he spent one year in Finland as an exchange student at the University of Helsinki. In 2016, he obtained his Master of Laws from New York University School of Law, and in 2017, he earned another Master of Laws from KoGuan Law School at Shanghai Jiao Tong University.
PRC Bar Qualification
New York State Bar Qualification
Chinese, English
